TARGETING UNMET GLOBAL NEEDS IN MULTI-BILLION DOLLAR MARKETS
review our transforming drug-delivery platforms
Virpax® Pharmaceuticals Inc., (Nasdaq: VRPX) is a publicly held specialty pharmaceutical company located in Berwyn, PA and is focused on advancing the development and worldwide commercialization of its non-addictive pain and neurological disorder pipeline.
Virpax’s transforming drug-delivery platforms and their targeted drug-releasing capabilities have been developed to enhance compliance and to optimize the efficacy of our non-addictive pain management pipeline and our Central Nervous System (CNS) disorder pipeline.
Virpax’s non-addictive pain management pipeline is being developed in collaboration with the National Institute of Health (NIH) and the Department of Defense (DoD). We anticipate advancing two pain assets into human trials in 2024. Once approved, these pain management alternatives may provide treatment options that help patients achieve better health outcomes.
Virpax is traded on
(Nasdaq: VRPX)
View our presentation
OPTIMIZING NON-ADDICTIVE DRUG DELIVERY
IN THE MANAGEMENT OF PAIN AND CNS DISORDERS, INCLUDING RARE AND ORPHAN DISEASES
Virpax is positioning its proprietary Rx pipeline to meet unmet needs in
three multi-billion dollar markets
Recent Press Releases
September 18, 2023
September 5, 2023
Recent Media
Aug 8, 2023
OUR MISSION
Our purpose is to develop innovative delivery platform technologies that optimize patient care worldwide in non-addictive pain and neurological disorders.
OUR VISION
We aspire to be a leader in addressing patient and provider needs worldwide in the management of pain and neurological disorders.
